Canaccord raised the firm’s price target on Edwards Lifesciences (EW) to $68 from $63 and keeps a Hold rating on the shares. The firm believes that the guidance issued at its investor conference is achievable and accounts for growth challenges being faced and potential future catalysts.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Early notable gainers among liquid option names on December 4th
- Edwards Lifesciences sees FY25 adjusted EPS $2.40-$2.50, consensus $2.47
- Edwards Lifesciences backs FY24 constant currency sales growth of 8%-10%
- Edwards Lifesciences price target raised to $88 from $85 at Barclays
- Edwards Lifesciences price target raised to $80 from $75 at RBC Capital